(Circulation. 1996;94:1553-1560.)
© 1996 American Heart Association, Inc.
Articles |
Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty
The EMPAR Study
the Departments of Medicine (J.A.C., J.G., J.H., D.H.) and Clinical Epidemiology and Biostatistics (J.A.C., R.R., M.G., J.H.), McMaster University, and the Departments of Medicine, University of Ottawa (B.M., J.F.M.), University of Western Ontario (K.F.), and University of Toronto (S.N., E.C.), Canada.
Correspondence to Dr John A. Cairns, Department of Medicine, Room 3W10, McMaster University Medical Centre, 1200 Main St W, Hamilton, Ontario, Canada L8N 3Z5. E-mail Cairns@FHS.CSU.McMaster.CA.
Background Percutaneous transluminal coronary angioplasty (PTCA) is complicated by restenosis within 6 months in >40% of patients. Theoretical, animal experimental, and human epidemiological and clinical trial findings have suggested that fish oils (n-3) might reduce restenosis. Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems.
Methods and Results We randomized 814 patients to fish oils (5.4 g n-3 fatty acids) or placebo a median of 6 days before PTCA and continued for 18 weeks. At the time of sheath removal, 653 patients with at least one successfully dilated lesion were randomized to LMWH (30 mg SC BID) or control for 6 weeks in a 2x2 factorial design. Follow-up with quantitative coronary angiography (QCA; target, 18 weeks) was interpretable on 96% of these patients. Restenosis rates per patient were for n-3, 46.5%; placebo, 44.7%; LMWH, 45.8%; and control, 45.4%. Restenosis rates per lesion were for n-3, 39.7%; placebo, 38.7%; LMWH, 38%; and control, 40.4%. At follow-up QCA, mean minimal lumen diameters were (mm) for n-3, 1.12; placebo, 1.10; LMWH, 1.12; and control, 1.10. Fifteen percent of patients permanently discontinued n-3/placebo before study completion, and 21% of patients discontinued LMWH early. There were no significant differences in the occurrences of ischemic events. Bleeding was more common with LMWH, usually was mild, and led to early discontinuation of study medication in only 0.9% of patients. Gastrointestinal side effects were more common in patients receiving n-3 than placebo.
Conclusions There is no evidence for a clinically important reduction of PTCA restenosis in this trial by either n-3 or LMWH. Evaluation of the results for n-3 in the context of previously published data on the reduction of PTCA restenosis indicates that n-3 is not efficacious and that further trials are unwarranted.
Key Words: angioplasty • restenosis • fish oils • heparin • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids Nutr Clin Pract, August 1, 2006; 21(4): 323 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, W. S Harris, M. Chung, A. H Lichtenstein, E. M Balk, B. Kupelnick, H. S Jordan, and J. Lau n-3 Fatty acids from fish or fish-oil supplements, but not {alpha}-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review Am. J. Clinical Nutrition, July 1, 2006; 84(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al. Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 184 - 221. [Full Text] [PDF]
|
|
|
|
|
|
A. T Erkkila, A. H Lichtenstein, D. Mozaffarian, and D. M Herrington Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease Am. J. Clinical Nutrition, September 1, 2004; 80(3): 626 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, S. E. Straus, D. L. Sackett, and D. G. Altman Analysis and Reporting of Factorial Trials: A Systematic Review JAMA, May 21, 2003; 289(19): 2545 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): e20 - 30. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease Circulation, November 19, 2002; 106(21): 2747 - 2757. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schweizer, A. Muller, L. Forkmann, G. Hellner, and W. Kirch Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty Angiology, October 1, 2001; 52(10): 659 - 669. [Abstract] [PDF]
|
|
|
|
|
|
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF]
|
|
|
|
|
|
J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris Circulation, February 6, 2001; 103(5): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. Underwood and S. M. Mitchell Low density lipoproteins in human plasma make vascular smooth muscle cells resistant to growth inhibition by heparin Cardiovasc Res, September 1, 2000; 47(4): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Ettenson and E. R Edelman Local drug delivery: an emerging approach in the treatment of restenosis Vascular Medicine, May 1, 2000; 5(2): 97 - 102. [Abstract] [PDF]
|
|
|
|
|
|
C. von Schacky n-3 Fatty acids and the prevention of coronary atherosclerosis1 Am. J. Clinical Nutrition, January 1, 2000; 71(1): 224S - 227S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pakala, R. Pakala, W. L. Sheng, and C. R. Benedict Eicosapentaenoic Acid and Docosahexaenoic Acid Block Serotonin-Induced Smooth Muscle Cell Proliferation Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2316 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Johansen, M. Brekke, I. Seljeflot, M. Abdelnoor, and H. Arnesen n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1619 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. von Schacky, P. Angerer, W. Kothny, K. Theisen, and H. Mudra The Effect of Dietary {omega}-3 Fatty Acids on Coronary Atherosclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, April 6, 1999; 130(7): 554 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]
|
|
|
|
|
|
A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Lablanche, E. P. McFadden, N. Meneveau, J. R. Lusson, B. Bertrand, J.-P. Metzger, V. Legrand, G. Grollier, C. Macaya, B. de Bruyne, et al. Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty : The FACT Study Circulation, November 18, 1997; 96(10): 3396 - 3402. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Weitz Low-Molecular-Weight Heparins N. Engl. J. Med., September 4, 1997; 337(10): 688 - 699. [Full Text] [PDF]
|
|